AXSM · Axsome Therapeutics, Inc.
$184.39
-1.75 (-0.94%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$9.75B
Shares
52.38M
Volume · Sep 30
1.03M
Avg daily vol (3M)
703.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$186.14
Open$191.41
Day$182.10–194.25
52W close$117.62–255.17
Avg vol 30d632K
Short int3.1M · 6.0% float · 5.2d
Short vol78%
Last earningsAug 10, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 6 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$776.57M
Trailing 12 months
Net income (TTM)
−$191.64M
Trailing 12 months
Revenue growth YoY
+45.5%
Year over year
Operating margin
-24.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$131.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
+58.3%
Trailing year
Short interest
6.0%
Latest settlement · 5.2 days to cover
AI Brief
Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26
TL;DR. Axsome delivered 46% YoY revenue growth to $218.4M led by Auvelity (+51%) and Sunosi (+20%), launched Auvelity in Alzheimer's disease agitation with early NBRx +126% in 65+ patients, and advanced its pipeline with FDA acceptance of the AXS-12 NDA (PDUFA May 1, 2027) and initiation of two ADHD Phase 3 trials.
Bullish
- + Total net product revenue grew 46% YoY to $218.4M with Auvelity up 51% and Sunosi up 20%.
- + Auvelity launched in Alzheimer's disease agitation in June 2026 with new-to-brand prescriptions up 126% in patients 65+ in the first eight weeks.
- + FDA accepted the AXS-12 NDA for cataplexy in narcolepsy with a PDUFA target action date of May 1, 2027.
- + Initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.
- + Payer coverage for Auvelity reached ~89% of lives (~82% commercial, ~100% government), supporting continued access expansion.
Bearish
- − Symbravo net sales declined $1.8M QoQ due to a prior period adjustment and elevated gross-to-net discounts in the high 80% range.
- − SG&A expenses surged 60% YoY to $208.1M driven by Auvelity sales force expansion and Symbravo launch activities.
- − Net loss widened to $51.3M ($0.99/share) versus a $48.0M loss a year ago, including $27.1M of stock-based compensation.
- − Auvelity gross-to-net discounts remain elevated at ~50% as Medicare scripts grow as a higher proportion of mix.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 16 · calm
Equity put/call 0.38
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−13%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+7%
trailing
YTD return
+2%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $213 › 200d $199 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +138 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.99% of float · ▲ +1.9% MoM · 5.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
511 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
EPS growth
+39%
Y/Y
Free cash flow
$-93.9M
Balance sheet
$135.2M
net cash
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
AUVELITY peak sales
· peak sales
at least $8B
SUNOSI peak sales
· peak sales
$300M – $500M
SYMBRAVO peak sales
· peak sales
$500M – $1B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $213 › 200d $199 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +138 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.99% of float · ▲ +1.9% MoM · 5.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
511 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $118
Now $186 · 50%
Range high $255
vs 200-day avg -7%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AUVELITY net product sales | $180.3M | Q2 2026 | — |
| AUVELITY payer coverage | 89% | Q2 2026 | — |
| AUVELITY total prescriptions | 266,000 | Q2 2026 | — |
| Commercial covered lives (AUVELITY) | 82% | 2Q 2026 | — |
| Commercial covered lives (SUNOSI) | 96% | 2Q 2026 | — |
| Commercial covered lives (SYMBRAVO) | 56% | 2Q 2026 | — |
| Patients treated since launch (AUVELITY) | 350,000 | 2Q 2026 | — |
| Patients treated since launch (SUNOSI) | 109,000 | 2Q 2026 | — |
| Patients treated since launch (SYMBRAVO) | 19,500 | 2Q 2026 | — |
| QoQ growth in activated new writers (AUVELITY) | 21% | 2Q 2026 | — |
| Sales force representatives | 630 | 2Q 2026 | — |
| SUNOSI net product revenue | $35.8M | Q2 2026 | — |
| SUNOSI payer coverage | 82% | Q2 2026 | — |
| SUNOSI prescriptions | 61,000 | Q2 2026 | — |
| SYMBRAVO net product sales | $2.3M | Q2 2026 | — |
| SYMBRAVO payer coverage | 57% | Q2 2026 | — |
| SYMBRAVO prescriptions | 23,500 | Q2 2026 | — |
| Unique writers since launch (AUVELITY) | 69,000 | 2Q 2026 | — |
| Unique writers since launch (SUNOSI) | 17,000 | 2Q 2026 | — |
| Unique writers since launch (SYMBRAVO) | 4,700 | 2Q 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AXSM
this stock
Axsome Therapeutics, Inc.
|
$9.75B | +1.9% | +65.5% | — | 6.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AXSM | -8.4% | -6.2% | +7.5% | -6.2% | +1.9% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -7.2% | -5.9% | -5.6% | -5.9% | -10.2% |